Contrasting Harrow (NASDAQ:HROW) & Aytu BioPharma (NASDAQ:AYTU)

Aytu BioPharma (NASDAQ:AYTU) and Harrow (NASDAQ:HROW) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Aytu BioPharma and Harrow’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Harrow	-13.51%	-38.00%	-3.37%

Insider & Institutional Ownership

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Aytu BioPharma and Harrow, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1	1	2	0	2.25
Harrow	1	2	9	0	2.67

Aytu BioPharma presently has a consensus target price of $10.75, indicating a potential upside of 445.69%. Harrow has a consensus target price of $66.38, indicating a potential upside of 94.02%. Given Aytu BioPharma’s higher probable upside, equities analysts clearly believe Aytu BioPharma is more favorable than Harrow.

Risk and Volatility

Aytu BioPharma has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.

Valuation & Earnings

This table compares Aytu BioPharma and Harrow”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38 million	0.32	-$13.56 million	($4.58)	-0.43
Harrow	$272.30 million	4.71	-$5.14 million	($1.00)	-34.21

Harrow has higher revenue and earnings than Aytu BioPharma. Harrow is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Summary

Harrow beats Aytu BioPharma on 11 of the 14 factors compared between the two stocks.

About Aytu BioPharma

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.